Literature DB >> 8306414

Accumulation of HL-60 leukemia cells in G2/M and inhibition of cytokinesis caused by two marine compounds, bistratene A and cycloxazoline.

D J Watters1, H J Beamish, K A Marshall, R A Gardiner, G J Seymour, M F Lavin.   

Abstract

The effects on the cell cycle of two biologically active compounds, bistratene A and cycloxazoline, from the marine ascidian Lissoclinum bistratum were studied in HL-60 human leukemia cells using flow cytometry. Both compounds were shown to cause an apparent accumulation of cells in the G2/M phase. This effect was shown to be both time- and dose-dependent. At the longer time points (30 and 48 h after addition of the compounds) polyploidy was apparent. The fate of cells labeled in the S phase with 5-bromo-2'-deoxyuridine (BrdUrd) was analysed using a bivariate BrdUrd/PI (propidium iodide) technique. Bistratene A and cycloxazoline treatment prevented the majority of BrdUrd-labeled cells from progressing through to the G1 phase. Approximately 50% of the cells were delayed at G2/M, and a significant proportion of cells appeared to be polyploid. Light and electron microscopy revealed the presence of multinucleated cells accounting for the apparent polyploidy. The progression of cells out of the G1 phase was also examined by synchronising cells with mimosine and releasing them from mimosine block in the presence of bistratene A. There was no evidence of a block at the G1/S phase transition or through the S phase since DNA synthesis was not inhibited. The mechanism by which these compounds interfere with cytokinesis is presently unknown but, in the case of bistratene A, may be linked to altered phosphorylation of cellular proteins involved in cell-cycle control.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8306414     DOI: 10.1007/BF00686269

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  22 in total

1.  Microfilament-disrupting Clostridium difficile toxin B causes multinucleation of transformed cells but does not block capping of membrane Ig.

Authors:  M C Shoshan; P Aman; S Skog; I Florin; M Thelestam
Journal:  Eur J Cell Biol       Date:  1990-12       Impact factor: 4.492

2.  Mechanism of inhibition of cell proliferation by Vinca alkaloids.

Authors:  M A Jordan; D Thrower; L Wilson
Journal:  Cancer Res       Date:  1991-04-15       Impact factor: 12.701

3.  Phosphorylation of cellular proteins in response to treatment with Clostridium difficile toxin B and Clostridium sordellii toxin L.

Authors:  J Ciesielski-Treska; G Ulrich; O Baldacini; H Monteil; D Aunis
Journal:  Eur J Cell Biol       Date:  1991-10       Impact factor: 4.492

4.  A new class of reversible cell cycle inhibitors.

Authors:  B D Hoffman; H M Hanauske-Abel; A Flint; M Lalande
Journal:  Cytometry       Date:  1991

5.  Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: neuromuscular toxicity is dose-limiting.

Authors:  D M Shin; P Y Holoye; W K Murphy; A Forman; S C Papasozomenos; W K Hong; M Raber
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  A rapid single step staining technique for DNA analysis by flow microfluorimetry.

Authors:  I W Taylor
Journal:  J Histochem Cytochem       Date:  1980-09       Impact factor: 2.479

7.  Effects of cytochalasins on mammalian cells.

Authors:  S B Carter
Journal:  Nature       Date:  1967-01-21       Impact factor: 49.962

8.  Phorbol ester-induced inhibition of proliferation of Daudi Burkitt's lymphoma cells by impairment of cytokinesis.

Authors:  J Menaya; M J Clemens
Journal:  Exp Cell Res       Date:  1991-06       Impact factor: 3.905

9.  Mimosine reversibly arrests cell cycle progression at the G1-S phase border.

Authors:  P A Watson; H H Hanauske-Abel; A Flint; M Lalande
Journal:  Cytometry       Date:  1991

10.  Clostridium difficile toxin A induces multinucleation in the human leukemic T cell line JURKAT.

Authors:  C Fiorentini; S C Chow; P Mastrantonio; M Jeddi-Tehrani; M Thelestam
Journal:  Eur J Cell Biol       Date:  1992-04       Impact factor: 4.492

View more
  8 in total

1.  Octaploid Meth-A cells are established from a highly polyploidized cell population.

Authors:  Kohzaburo Fujikawa-Yamamoto; Hiroko Yamagishi; Minoru Miyagoshi
Journal:  Cell Prolif       Date:  2003-04       Impact factor: 6.831

2.  Establishment of a triploid V79 cell line from tetraploid cells obtained through polyploidization using K-252a.

Authors:  Kohzaburo Fujikawa-Yamamoto; Hiroko Yamagishi; Minoru Miyagoshi
Journal:  Cell Prolif       Date:  2002-12       Impact factor: 6.831

3.  Stimulation of protein kinase C-dependent and -independent signaling pathways by bistratene A in intestinal epithelial cells.

Authors:  M R Frey; O Leontieva; D J Watters; J D Black
Journal:  Biochem Pharmacol       Date:  2001-05-01       Impact factor: 5.858

Review 4.  Antitumor peptides from marine organisms.

Authors:  Lan-Hong Zheng; Yue-Jun Wang; Jun Sheng; Fang Wang; Yuan Zheng; Xiu-Kun Lin; Mi Sun
Journal:  Mar Drugs       Date:  2011-10-10       Impact factor: 6.085

Review 5.  Recent Advances in Small Peptides of Marine Origin in Cancer Therapy.

Authors:  Qi-Ting Zhang; Ze-Dong Liu; Ze Wang; Tao Wang; Nan Wang; Ning Wang; Bin Zhang; Yu-Fen Zhao
Journal:  Mar Drugs       Date:  2021-02-19       Impact factor: 5.118

6.  Cell cycle perturbations and apoptosis induced by isohomohalichondrin B (IHB), a natural marine compound.

Authors:  D Bergamaschi; S Ronzoni; S Taverna; M Faretta; P De Feudis; G Faircloth; J Jimeno; E Erba; M D'Incalci
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

Review 7.  Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.

Authors:  Kelly C L Mulder; Loiane A Lima; Vivian J Miranda; Simoni C Dias; Octávio L Franco
Journal:  Front Microbiol       Date:  2013-10-31       Impact factor: 5.640

Review 8.  Therapeutic Properties and Biological Benefits of Marine-Derived Anticancer Peptides.

Authors:  Hee Kyoung Kang; Moon-Chang Choi; Chang Ho Seo; Yoonkyung Park
Journal:  Int J Mol Sci       Date:  2018-03-20       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.